药学干预对肝癌中晚期癌痛化疗的影响分析  

Analysis of the Effect of Clinical Pharmaceutical Intervention on Chemotherapy for Cancer Pain in Advanced Liver Cancer

作　　者：郑佳 罗岚[2] 周传意 ZHENG Jia;LUO Lan;ZHOU Chuanyi(Department of Basic Medicine,Yueyang Vocational Technical College,Yueyang 414000,China;Medical College,Yueyang Vocational Technical College,Yueyang 414000,China;The Third Department of Oncology,Yueyang People’s Hospital,Yueyang 414000,China)

机构地区：[1]岳阳职业技术学院基础医学部,湖南岳阳414000 [2]岳阳职业技术学院医学院,湖南岳阳414000 [3]岳阳市人民医院肿瘤三科,湖南岳阳414000

出　　处：《湖南理工学院学报（自然科学版）》2022年第3期58-61,共4页Journal of Hunan Institute of Science and Technology(Natural Sciences)

基　　金：湖南省教育厅科学研究项目“临床药学干预对肝癌中晚期癌痛及化疗的影响分析”(21C1540)。

摘　　要：探讨临床药学干预对肝癌中晚期癌痛患者化疗疗效及依从性的影响.选取某大型综合性医院135名肝癌中晚期癌痛住院患者,将其随机分为常规组、干预A组和干预B组三组,分别实施常规用药、用药干预为核心、用药干预结合用药教育为核心的临床药学干预,分别采用NRS疼痛评分量表、化疗知信行KAP问卷,分析临床药学干预对肝癌中晚期癌痛患者化疗疗效及患者依从性的影响.三组患者年龄、性别、病程差异均无统计学意义(P>0.05).干预前三组患者NRS评分无差异(P>0.05),干预后干预B组患者NRS评分降低程度、疼痛有效缓解率分别高于其他两组(P<0.001).干预A组和B组患者便秘、恶心发生率较干预前显著降低,以干预B组较明显(P<0.05).干预A组和B组患者K、A、P得分均较干预前提高,干预B组优于A组(P<0.001),常规组患者仅K得分有所提高.临床药学干预有助于缓解肝癌中晚期患者癌性疼痛,减少不良反应,增加患者对癌痛知识的认知和掌握,提高依从性,可在肝癌患者临床治疗中推广.The effect and compliance of clinical pharmaceutical intervention on the chemotherapy for the patients with cancer pain in advanced stage of liver cancer was discussed.135 advanced stage cancer pain of liver cancer patients in a large comprehensive hospital were selected and randomly divided into three groups:routine group,intervention group A and intervention group B.Pharmaceutical intervention with routine medication guidance,medication intervention as the core,medication intervention and medication education as the core were carried out separately.NRS pain score scale and KAP questionnaire were used to analyze the clinical effect of pharmaceutical intervention and impact of compliance in the patients.There is no significant difference in age,gender and disease course among the three groups(P > 0.05).There is no significant difference in NRS score among the three groups before intervention(P > 0.05).After intervention,the NRS score reduction and effective pain relief rate of group B are higher than those of the other two groups(P < 0.001).The incidence of adverse reaction such as constipation and nausea in intervention group A and group B is significantly reduced than that before intervention,and the decrease in intervention group B was more obvious(P < 0.05).The K,A and P scores of the intervention group A and B are higher than those before intervention,and the score improvement of intervention group B is better than that of intervention group A(P < 0.001),the patients of routine group only the K score is improved.Clinical pharmaceutical intervention is helpful to relieve cancer pain of the patients with advanced liver cancer,reduce adverse reactions,increase cognition and mastery of cancer pain knowledge,and improve compliance of patients,which could be popularized in the clinical treatment of patients with liver cancer.

关 键 词：临床药学干预 肝癌中晚期 癌痛 化疗疗效 依从性 

分 类 号：R735.3[医药卫生—肿瘤]